title: Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.
abstract: A transient subgenomic replicon-based shuttle vector system has been developed to investigate how genetic heterogeneity affects HCV replication efficiency. Individual NS5A or NS5B genes or cassettes containing both NS5A and NS5B genes were amplified from "quasispecies" pools derived from HCV genotype 1a or 1b patient sera using RT-PCR and cloned into their respective shuttle vectors. All shuttle vectors containing NS5A or NS5A-5B genes were constructed with the S2204I "adaptive" mutation because replicons lacking the S2204I mutation replicated poorly. Gene sequences of the quasispecies pools within either genotype 1a or 1b patient samples ranged from 94 to 95% in identity. The replication capacity of 1b shuttle vectors containing patient-derived NS5A or NS5B genes averaged 67 and 75%, respectively, relative to the laboratory-optimized 1b replicon. In contrast, the replication efficiencies of both 1a and 1b shuttle vectors containing patient-derived NS5A-5B gene cassettes averaged around 2% relative to the respective laboratory-optimized replicon. All patient-derived replicons were tested in a transient assay for their sensitivity to either interferon-alpha (IFN-alpha) or to the polymerase inhibitor A-782759. Despite the differences in replication efficiency, IC(50) values measured for most of the patient-derived replicons were equivalent to the respective values measured in the control laboratory strain replicons. These results demonstrate that patient sequence heterogeneity affects replication efficiency whenever patient-derived NS5A-5B genes are inserted into the laboratory-optimized replicon. The findings also demonstrate the utility of the shuttle vector system to test patient-derived gene sequences for sensitivity to IFN-alpha and to small molecule inhibitors.
authors.affiliation: Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. rakesh.1.tripathi@abbott.com
authors.forename: Rakesh L
authors.initials: RL
authors.lastname: Tripathi
authors.forename: Preethi
authors.initials: P
authors.lastname: Krishnan
authors.forename: Yupeng
authors.initials: Y
authors.lastname: He
authors.forename: Tim
authors.initials: T
authors.lastname: Middleton
authors.forename: Tami
authors.initials: T
authors.lastname: Pilot-Matias
authors.forename: Chih-Ming
authors.initials: CM
authors.lastname: Chen
authors.forename: Daryl T Y
authors.initials: DT
authors.lastname: Lau
authors.forename: Stanley M
authors.initials: SM
authors.lastname: Lemon
authors.forename: Hongmei
authors.initials: H
authors.lastname: Mo
authors.forename: Warren
authors.initials: W
authors.lastname: Kati
authors.forename: Akhteruzzaman
authors.initials: A
authors.lastname: Molla
mesh_terms: D045744:Cell Line, Tumor; D005822:Genetic Vectors; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D006526:Hepatitis C / Q000821:virology*; D006801:Humans; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000378:metabolism; D012093:Replicon; D017361:Viral Nonstructural Proteins / Q000235:genetics* / Q000378:metabolism; D014779:Virus Replication; D012324:RNA-Dependent RNA Polymerase
chemical_list: D011993:Recombinant Fusion Proteins; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase